Across the United States, a quiet shift in HIV policy is raising alarms among public health advocates. As of March 2026, at least 18 states have reduced or restricted access to AIDS Drug Assistance Programs (ADAP), with five more considering similar changes.
The Rising Cost of Staying Alive
ADAP programs, funded through the federal Ryan White HIV/AIDS Program, are a critical lifeline for roughly 300,000 Americans living with HIV – about a quarter of the nation’s HIV-positive population. These programs aid individuals afford life-saving medications that can cost tens of thousands of dollars annually. The core issue? Soaring medication costs. Biktarvy, the most widely prescribed HIV medication, now costs approximately $61,000 per year at wholesale.
A Perfect Storm of Challenges
The restrictions on ADAP come at a time of increased require. Enrollment in these programs has surged roughly 30 percent in recent years, largely due to Americans losing Medicaid coverage as pandemic-era protections expired. Simultaneously, enhanced Affordable Care Act tax credits expired at the end of 2025, driving up insurance premiums by roughly 26 percent between 2025 and 2026. Federal funding for the Ryan White program, however, has remained largely flat for over a decade, failing to keep pace with rising costs.
Disproportionate Impact on Black Communities
The consequences of these cuts will not be felt equally. Black Americans represent more than 40 percent of new HIV diagnoses, despite comprising only 13 percent of the U.S. Population. This disparity is particularly pronounced among Black women, who account for over 50 percent of new diagnoses, and Black transgender women, who account for 46 percent. Many of the states implementing restrictions are located in the South, where HIV rates are highest and a significant portion of the Black population resides.
The Risks of Treatment Interruption
Interruptions in HIV medication can have serious consequences. Stopping treatment can allow the virus to rebound and develop resistance to medication, potentially rendering future treatments ineffective. Consistent medication is essential for suppressing the virus and preventing transmission.
Beyond Health: Economic and National Implications
The cuts to ADAP also undermine national goals. President Trump set a goal in 2019 to end the HIV epidemic by 2030, but these funding reductions move the nation in the opposite direction. Beyond the human cost, interruptions in preventive care can lead to higher emergency healthcare costs, increased hospitalizations, and a greater strain on public health systems.
What Can Be Done?
Advocates emphasize several key actions individuals can take. Knowing your HIV status is paramount, and organizations like the National Black Justice Collective offer free at-home testing kits. If you lose coverage, do not stop treatment; consult a healthcare provider. Contact your local AIDS service organization for assistance with emergency medication programs. Crucially, advocates are calling for increased federal funding for the Ryan White program and urging individuals to pressure policymakers.
Supporting organizations working within affected communities, such as the Black AIDS Institute, the National Black Justice Collective, and TruEvolution, is also vital. Staying informed and engaged in policy conversations is essential.
FAQ
Q: What is ADAP?
A: AIDS Drug Assistance Programs help people living with HIV afford life-saving medications.
Q: Why are ADAP programs being cut?
A: States are citing cost-cutting measures, despite rising medication prices and increased enrollment.
Q: Who is most affected by these cuts?
A: Black Americans, particularly Black women and Black transgender women, are disproportionately impacted.
Q: What can I do to help?
A: Get tested, stay in treatment if you’re positive, contact your policymakers, and support relevant organizations.
